- NervGen Pharma (NGEN) is granting 150,000 incentive stock options
- Stocks are offered at C$1.99 per share for first 5 years
- NervGen (NGEN) is a clinical biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease.
- NervGen Pharma (NGEN) is currently trading at C$1.97 as of 11:30am ET
NervGen Pharma (NGEN) announced that it is granting 150,000 incentive stock options.
The company focuses on clinical-stage biotech and is dedicated to developing a first-in-class neutoreparative drug to treat nervous system damage. The stock is offered at C$1.99 per share for five years. The incentive stock option will vest equally every three months for one year. All options are granted in accordance with the policies of the TSX Venture Exchange and the conditions of the company’s stock option plan.
NervGen (NGEN) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease.
NervGen Pharma (NGEN) is currently trading at C$1.97 as of 11:30am ET.
